Antineoplastic drugs that interfere with iron metabolism in cancer cells.
about
Bioengineering strategies for designing targeted cancer therapiesAntitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drugAdministration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.Evaluation of Nonferrous Metals as Potential In Vivo Tracers of Transferrin-Based Therapeutics.An RNA alternative to human transferrin: a new tool for targeting human cells.The transferrin receptor and the targeted delivery of therapeutic agents against cancer.The anti-tumour agent, cisplatin, and its clinically ineffective isomer, transplatin, produce unique gene expression profiles in human cellsDesferal regulates hCtr1 and transferrin receptor expression through Sp1 and exhibits synergistic cytotoxicity with platinum drugs in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo.Docetaxel nanotechnology in anticancer therapy.Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells.Transferrin receptor-mediated endocytosis: a useful target for cancer therapy.Identification of the molecular mechanisms underlying the cytotoxic action of a potent platinum metallointercalator.Differing sensitivity of tumor cells to apoptosis induced by iron deprivation in vitro.Desferri-exochelin induces death by apoptosis in human breast cancer cells but does not kill normal breast cells.The effects of desferrioxamine on cisplatin-induced lipid peroxidation and the activities of antioxidant enzymes in rat kidneys.Iron metabolism and drug resistance in cancer.Indium/Gallium Maltolate Effects on Human Breast Carcinoma Cells: In Vitro Investigation on Cytotoxicity and Synergism with Mitoxantrone.
P2860
Q34194191-74C8C125-7BB2-4E4E-9705-6B738406E89DQ35585226-4D1A5664-2284-49B6-8C6E-DA6280BB8E1AQ35691719-A1B1C6F9-5AC3-4218-A218-29276594BA00Q35782785-16E50C07-5D6D-45F1-BFA9-11D6D0E8451CQ36077849-AAA23BCC-AC1F-4887-9216-B4651D0A5A45Q36406637-2CA528D4-37CF-47F3-8616-0B39C0FB2B7CQ37055940-165619E5-4705-43ED-AE71-03E119069ABDQ37580222-DE4BF51C-11A8-4032-A8E0-920394192DB6Q38003964-DBF2F90D-A62A-4D03-B667-D4FAE0221A4FQ38104410-628C4AB7-678D-402F-9F9C-6B5FD49F86C0Q38191445-767D3E49-E544-4855-86B5-E4ADE2EED056Q39229225-41530AF2-7C46-406F-8FE1-40B69F948AC5Q43748453-1CFA3BE7-E8C3-4A0E-AEF7-CFEE50F06AF8Q43835720-1E59CEEE-8AEB-41DE-98F4-A5C999969441Q44803416-6F9E47BF-4EEF-49C7-B6FD-9DAC2AF25785Q48001406-5A00D620-93D1-45D2-8023-E30216C5CDAFQ55691126-1EAB34B0-4CDD-4E8D-88B2-9195772B2E09
P2860
Antineoplastic drugs that interfere with iron metabolism in cancer cells.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Antineoplastic drugs that interfere with iron metabolism in cancer cells.
@en
type
label
Antineoplastic drugs that interfere with iron metabolism in cancer cells.
@en
prefLabel
Antineoplastic drugs that interfere with iron metabolism in cancer cells.
@en
P2093
P1476
Antineoplastic drugs that interfere with iron metabolism in cancer cells.
@en
P2093
P304
P356
10.1016/S0065-2571(96)00010-6
P577
1997-01-01T00:00:00Z